PD-L1 生物检测在癌症免疫治疗中的临床应用。
Clinical applications of PD-L1 bioassays for cancer immunotherapy.
机构信息
Department of Oncology, The first Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
The Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital, Beijing, China.
出版信息
J Hematol Oncol. 2017 May 17;10(1):110. doi: 10.1186/s13045-017-0479-y.
Abstract
Programmed death ligand 1 (PD-L1) has emerged as a biomarker that can help to predict responses to immunotherapies targeted against PD-L1 and its receptor (PD-1). Companion tests for evaluating PD-L1 expression as a biomarker of response have been developed for many cancer immunotherapy agents. These assays use a variety of detection platforms at different levels (protein, mRNA), employ diverse biopsy and surgical samples, and have disparate positivity cutoff points and scoring systems, all of which complicate the standardization of clinical decision-making. This review summarizes the current understanding and ongoing investigations regarding PD-L1 expression as a potential biomarker for clinical outcomes of anti-PD-1/PD-L1 immunotherapy.
摘要
程序性死亡配体 1（PD-L1）已成为一种生物标志物，可以帮助预测针对 PD-L1 及其受体（PD-1）的免疫疗法的反应。已经为许多癌症免疫治疗药物开发了评估 PD-L1 表达作为反应生物标志物的伴随检测。这些检测使用不同水平（蛋白质、mRNA）的各种检测平台，采用不同的活检和手术样本，具有不同的阳性截止点和评分系统，所有这些都使临床决策的标准化变得复杂。本综述总结了目前对 PD-L1 表达作为抗 PD-1/PD-L1 免疫治疗临床结局的潜在生物标志物的理解和正在进行的研究。
相似文献
1
Clinical applications of PD-L1 bioassays for cancer immunotherapy.PD-L1 生物检测在癌症免疫治疗中的临床应用。
J Hematol Oncol. 2017 May 17;10(1):110. doi: 10.1186/s13045-017-0479-y.
2
Biomarkers for PD-1/PD-L1 Blockade Therapy in Non-Small-cell Lung Cancer: Is PD-L1 Expression a Good Marker for Patient Selection?非小细胞肺癌中PD-1/PD-L1阻断疗法的生物标志物：PD-L1表达是患者选择的良好标志物吗？
Clin Lung Cancer. 2016 Sep;17(5):350-361. doi: 10.1016/j.cllc.2016.03.011. Epub 2016 Apr 6.
3
Agreement between Programmed Cell Death Ligand-1 Diagnostic Assays across Multiple Protein Expression Cutoffs in Non-Small Cell Lung Cancer.不同程序性死亡配体-1 诊断检测试剂用于非小细胞肺癌不同蛋白表达截断值时的一致性。
Clin Cancer Res. 2017 Jul 15;23(14):3585-3591. doi: 10.1158/1078-0432.CCR-16-2375. Epub 2017 Jan 10.
4
[PD1/PD-L1 immunohistochemistry in thoracic oncology: Where are we?].[胸部肿瘤学中的PD1/PD-L1免疫组织化学：我们目前的进展如何？]
Ann Pathol. 2017 Feb;37(1):39-45. doi: 10.1016/j.annpat.2016.12.006. Epub 2017 Jan 31.
5
Cancer immunotherapy using PolyPurine Reverse Hoogsteen hairpins targeting the PD-1/PD-L1 pathway in human tumor cells.使用靶向 PD-1/PD-L1 通路的 PolyPurine Reverse Hoogsteen 发夹的癌症免疫疗法在人类肿瘤细胞中。
PLoS One. 2018 Nov 6;13(11):e0206818. doi: 10.1371/journal.pone.0206818. eCollection 2018.
6
Pan-cancer analysis of copy number changes in programmed death-ligand 1 (PD-L1, CD274) - associations with gene expression, mutational load, and survival.程序性死亡配体1（PD-L1，CD274）拷贝数变化的泛癌分析——与基因表达、突变负荷及生存的关联
Genes Chromosomes Cancer. 2016 Aug;55(8):626-39. doi: 10.1002/gcc.22365. Epub 2016 May 30.
7
8
Progress and challenges of predictive biomarkers of anti PD-1/PD-L1 immunotherapy: A systematic review.抗 PD-1/PD-L1 免疫治疗预测生物标志物的研究进展与挑战：系统综述。
Cancer Lett. 2018 Feb 1;414:166-173. doi: 10.1016/j.canlet.2017.11.014. Epub 2017 Nov 16.
9
PD-L1 immunohistochemistry for non-small cell lung carcinoma: which strategy should be adopted?PD-L1 免疫组织化学检测在非小细胞肺癌中的应用：应采用哪种策略？
Expert Rev Mol Diagn. 2017 Dec;17(12):1097-1108. doi: 10.1080/14737159.2017.1398083. Epub 2017 Nov 1.
10
Status of Programmed Death Ligand 1 (PD-L1) by Immunohistochemistry and Scoring Algorithms.程序性死亡配体 1（PD-L1）免疫组化和评分算法的状况。
Curr Drug Targets. 2020;21(13):1286-1292. doi: 10.2174/1389450121666200123124642.
引用本文的文献
1
The Challenges and Opportunities of Protein Coronas for Nanoscale Biomolecular Sensing.蛋白质冠层在纳米级生物分子传感中的挑战与机遇
Small. 2025 Sep;21(36):e03820. doi: 10.1002/smll.202503820. Epub 2025 Jul 26.
2
Peripheral inflammatory factors as prognostic predictors for first-line PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer.外周炎症因子作为晚期非小细胞肺癌一线PD-1/PD-L1抑制剂预后预测指标
Sci Rep. 2025 Apr 2;15(1):11206. doi: 10.1038/s41598-024-84469-y.
3
A Novel Prognostic Signature of Mitophagy-Related E3 Ubiquitin Ligases in Breast Cancer.一种乳腺癌中线粒体自噬相关E3泛素连接酶的新型预后标志物。
Int J Mol Sci. 2025 Feb 12;26(4):1551. doi: 10.3390/ijms26041551.
4
Association of pre-existing conditions with major driver mutations and PD-L1 expression in NSCLC.非小细胞肺癌中既往存在的疾病与主要驱动基因突变及程序性死亡受体配体1（PD-L1）表达的关联
BMJ Open Respir Res. 2024 Dec 4;11(1):e002571. doi: 10.1136/bmjresp-2024-002571.
5
Prognostic biomarkers for immunotherapy in esophageal cancer.食管癌免疫治疗的预后生物标志物。
Front Immunol. 2024 Sep 30;15:1420399. doi: 10.3389/fimmu.2024.1420399. eCollection 2024.
6
Prediction of PD-L1 and Ki-67 status in primary central nervous system diffuse large B-cell lymphoma by diffusion and perfusion MRI: a preliminary study.通过扩散和灌注 MRI 预测原发性中枢神经系统弥漫性大 B 细胞淋巴瘤的 PD-L1 和 Ki-67 状态：一项初步研究。
BMC Med Imaging. 2024 Aug 26;24(1):222. doi: 10.1186/s12880-024-01409-y.
7
Programmed Death Ligand 1 (PD-L1) Expression in Lymphomas: State of the Art.程序性死亡配体 1（PD-L1）在淋巴瘤中的表达：最新进展。
Int J Mol Sci. 2024 Jun 11;25(12):6447. doi: 10.3390/ijms25126447.
8
Tumor immune escape: extracellular vesicles roles and therapeutics application.肿瘤免疫逃逸：细胞外囊泡的作用和治疗应用。
Cell Commun Signal. 2024 Jan 2;22(1):9. doi: 10.1186/s12964-023-01370-3.
9
Immune checkpoint analysis in ear cancer.耳部癌症的免疫检查点分析。
Head Face Med. 2023 Nov 6;19(1):48. doi: 10.1186/s13005-023-00395-w.
10
Development of a Highly Sensitive Hybrid LC/MS Assay for the Quantitative Measurement of CTLA-4 in Human T Cells.开发一种高灵敏度的混合 LC/MS 测定法，用于定量测量人 T 细胞中的 CTLA-4。
Molecules. 2023 Apr 8;28(8):3311. doi: 10.3390/molecules28083311.
本文引用的文献
1
PD-L1 (CD274) copy number gain, expression, and immune cell infiltration as candidate predictors for response to immune checkpoint inhibitors in soft-tissue sarcoma.PD-L1（CD274）拷贝数增加、表达及免疫细胞浸润作为软组织肉瘤对免疫检查点抑制剂反应的候选预测指标
Oncoimmunology. 2017 Jan 27;6(3):e1279777. doi: 10.1080/2162402X.2017.1279777. eCollection 2017.
2
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response.PD-L1免疫组化检测在预测PD-1/PD-L1抑制剂反应中的应用。
Biomark Res. 2017 Mar 15;5:12. doi: 10.1186/s40364-017-0093-8. eCollection 2017.
3
High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer.高血浆可溶性程序性死亡配体 1 水平与晚期肺癌患者生存降低相关。
Lung Cancer. 2017 Feb;104:1-6. doi: 10.1016/j.lungcan.2016.11.023. Epub 2016 Dec 5.
4
Tumor-infiltrating lymphocyte composition, organization and PD-1/ PD-L1 expression are linked in breast cancer.肿瘤浸润淋巴细胞的组成、组织方式及PD-1/PD-L1表达在乳腺癌中存在关联。
Oncoimmunology. 2016 Dec 14;6(1):e1257452. doi: 10.1080/2162402X.2016.1257452. eCollection 2017.
5
Heterogeneity in Immune Marker Expression after Acquisition of Resistance to EGFR Kinase Inhibitors: Analysis of a Case with Small Cell Lung Cancer Transformation.获得 EGFR 激酶抑制剂耐药后免疫标志物表达的异质性：小细胞肺癌转化病例分析。
J Thorac Oncol. 2017 Jun;12(6):1015-1020. doi: 10.1016/j.jtho.2017.02.002. Epub 2017 Feb 11.
6
The significance of programmed cell death ligand 1 expression in resected lung adenocarcinoma.程序性细胞死亡配体1表达在肺腺癌切除标本中的意义
Oncotarget. 2017 Mar 7;8(10):16421-16429. doi: 10.18632/oncotarget.14851.
7
PD-1, PD-L1 (B7-H1) and Tumor-Site Immune Modulation Therapy: The Historical Perspective.程序性死亡受体1、程序性死亡配体1（B7-H1）与肿瘤部位免疫调节治疗：历史视角
J Hematol Oncol. 2017 Jan 25;10(1):34. doi: 10.1186/s13045-017-0403-5.
8
Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% Expression in Lung Adenocarcinoma.EGFR、ALK或ROS1中经典驱动癌基因突变与肺腺癌中22C3-PD-L1≥50%表达之间的相关性
J Thorac Oncol. 2017 May;12(5):878-883. doi: 10.1016/j.jtho.2016.12.026. Epub 2017 Jan 16.
9
Agreement between Programmed Cell Death Ligand-1 Diagnostic Assays across Multiple Protein Expression Cutoffs in Non-Small Cell Lung Cancer.不同程序性死亡配体-1 诊断检测试剂用于非小细胞肺癌不同蛋白表达截断值时的一致性。
Clin Cancer Res. 2017 Jul 15;23(14):3585-3591. doi: 10.1158/1078-0432.CCR-16-2375. Epub 2017 Jan 10.
10
Bladder cancer: Atezolizumab: an alternative to cisplatin?膀胱癌：阿替利珠单抗：顺铂的替代药物？
Nat Rev Urol. 2017 Feb;14(2):67. doi: 10.1038/nrurol.2016.271. Epub 2016 Dec 29.
Zotero 插件